Institute for Innovative Cancer Research, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea.
Cancer Lett. 2013 May 10;332(1):102-9. doi: 10.1016/j.canlet.2013.01.022. Epub 2013 Jan 21.
In this study, we investigated the antitumor effects of deguelin in several human breast cancer cells in vitro and in vivo. Deguelin inhibited cell viability and the anchorage-dependent and anchorage-independent colony formation of triple-negative (MDA-MB-231 and MDA-MB-468) and triple-positive (MCF-7) breast cancer cells, and it significantly reduced the growth of MCF-7 cell xenograft tumors. The induction of apoptosis, inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling activation, and up-regulation of IGF-binding protein-3 (IGFBP-3) expression may be associated with deguelin-mediated antitumor effects. Our findings suggest a potential therapeutic use for deguelin in patients with triple-negative breast cancer and for those with breast cancers who are sensitive to endocrine- and HER2-targeted therapies.
在这项研究中,我们研究了去氢骆驼蓬碱在体外和体内对几种人乳腺癌细胞的抗肿瘤作用。去氢骆驼蓬碱抑制三阴性(MDA-MB-231 和 MDA-MB-468)和三阳性(MCF-7)乳腺癌细胞的活力以及锚定依赖性和非锚定依赖性集落形成,并显著减少 MCF-7 细胞异种移植肿瘤的生长。凋亡的诱导、胰岛素样生长因子-1 受体(IGF-1R)信号激活的抑制和 IGF 结合蛋白-3(IGFBP-3)表达的上调可能与去氢骆驼蓬碱介导的抗肿瘤作用有关。我们的研究结果表明,去氢骆驼蓬碱在三阴性乳腺癌患者以及对内分泌和 HER2 靶向治疗敏感的乳腺癌患者中具有潜在的治疗用途。